Advanced International Breast Cancer Course (AIBCC)

Aims

Mortality from breast cancer is declining in most countries thanks to effective screening programs, early diagnosis, molecular characterization of the different subtypes and biology-driven treatments. A multidisciplinary management of breast cancer patients is therefore the key to success and a breast multidisciplinary team should include - besides the “classic” clinical specialties - pathologists, molecular biologists and geneticists. Furthermore, the availability of multiple diagnostic and therapeutic choices, the increasing costs of new technologies and drugs and the issue of sustainability represent a new challenge for socially-responsible clinicians. With this goal in mind, the Programme includes lectures on molecular characterization, updated treatments of early and advanced disease, management of difficult cases and hereditary syndromes and issues of sustainability and drug access across countries.

Clinical case discussions and debates are planned to allow a continuous and fruitful exchange of experiences and opinions between speakers and participants.

This 16^th Breast Cancer Conference includes highly qualified international faculty, but will maintain its characteristics of a friendly forum where opinion leaders and attendees might exchange experiences and share the most exiting advances.

In order to reward scientific excellence and to foster international cooperation, the International Scientific Committee of the 16th AIBCC will award the 10th International Prize for Breast Cancer Research to a scientist who has published a breakthrough paper in the previous year. We also welcome the presentation of posters from participants and the best poster will be awarded during the Award Ceremony.

The Conference is addressed to medical oncologists, pathologists, breast surgeons, radiation oncologists and basic scientists who will have the opportunity to interact with breast cancer leaders and exchange experiences in a friendly atmosphere.

Addressed to

Gynaecologists and obstetrics, medical oncologists, pathologists, radiologists, radiation oncologists, surgeons. Biologists, pharmacists, and nurses.

CME

Based on Italian regulations, Accademia Nazionale di Medicina (provider n. 31) will request the MCE Accreditation.

The credit certification is subject to:

• Professions/specializations should correspond to those which have been accredited for CME;
• 90% attendance to the meeting;
• Completion of the meeting evaluation form;
• Completion of the final questionnarie (at least 75% of correct answers).

We would like to remind you to participants that only 1/3 of CME credits acquired during the years 2020/2022 can come from a sponsorship.

Official Language

The official language of the Meeting is English. No simultaneous translation will be provided.

University of Padua award for advances in breast cancer 2020

The Scientific Committee will select young researchers (< 40 years from any country) who have published in an international peer-reviewed journal, as the principal author, a manuscript reporting important clinical or biological advances in breast cancer. The winner will be invited to present his/her study during the annual Conference.

Fellowships

Some fellowship (for under 40) will be awarded which will include registration and 3 Hotel nights. Those interested should send the registration form together with a short CV and a motivation letter within July 21^st.
The organizing secretariat will confirm the award of the fellowship within July 30^th and it will proceed with the organization of logistics.

Free admission is available for a few people “under 40”. Registration forms will be accepted on a first-come, first-served basis unitil spaces are filled. The Organization Secretariat will confirm the registration by email.

Thursday, October 8^th

8.30

Registration

9.15

Introduction to the Conference
Pier Franco Conte, Gabriel N. Hortobagyi, Valentina Guarneri, Philip Poortmans

 

SESSION I – BREAST CANCER PREVENTION

9.30

Breast cancer screening: towards individualized programs

9.50

Risk reducing strategies for BRCA + BC

10.10

Beyond BRCA1/2: Management of women with other predisposition gene mutations

10.30

Q&A

10.50

Coffee break

 

SESSION II - LOCOREGIONAL TREATMENT

11.10

Is it safe to avoid axillary node dissection in SN+ patients?

11.30

Options for breast reconstruction

11.50

PMRT after immediate breast reconstruction: the way forward

12.10

Rare consequences of Breast Implants: Anaplastic Large Cell Lymphoma

12.30

Q&A

13.00

Lunch

14.00

Multidisciplinary Tumor Board 1 – Locoregional treatment

• Clinical case: margins in DCIS
• Clinical case: sentinel node biopsy before/after primary systemic therapy
• Clinical case: partial breast irradiation
• Clinical case: radiation therapy after primary systemic therapy treatment (cN+downstaged to ypN0)
• Clinical case: breast reconstruction after neoadjuvant CT (tissue expander vs tram flap, immmediate vs delayed; safety of radiotherapy)

 

SESSION III – LIFE AFTER BREAST CANCER

15.30

Hormone replacement therapy after BC treatment

15.50

Bone Health

16.10

Cardiovascular consequences

16.30

Follow up: how, who, why

16.50

Q&A

17.00

COFFEE WITH PROFESSORS

18.00

Adjourn

Friday, October 9^th

8.00

Poster display & discussion

 

SESSION IV – PATHOLOGY, GENOMICS & MOLECULAR BIOLOGY

9.00

Tumor infiltrating lymphocytes in breast cancer: role in clinical practice

9.20

Clinical impact of genomics for HER2+ and TNBC

9.40

New biomarkers ready for prime time (PDL1, PI3K, BRCA, AR etc)

10.00

Q&A

10.20

Coffee Break

 

SESSION V – SYSTEMIC TREATMENTS FOR EARLY BREAST CANCER

11.00

How to identify HR+ who are likely to benefit from adjuvant chemotherapy

11.20

Risk adapted endocrine therapy for HR+ BC (from 5 y tamoxifen to 10 years or more AI)

11.40

Neoadjuvant therapy for HER2+ disease: new data, new standard?

12.00

Is immunotherapy ready for prime time for eTNBC?

12.20

Neoadjuvant vs Post-neoadjuvant treatments: PROs and CONs

12.40

Q&A

13.00

Lunch

14.00

Multidisciplinary Tumor Board 2 - Early breast cancer
How to manage:

• Clinical case: pathologic complete response after CT+trastuzumab and pertuzumab?
• Clinical case: young patients with TNBC and BRCA+ (discussion on platinum salts, ovarian stimulation for fertility issues, contralateral surgery)
• Clinical case: patients with luminal tumor with positive SN not undergoing axillary dissection (overtesting with prognostic assays? Risk of Overtreatment?)
• Clinical case: rare histology

 

SESSION VI – ADVANCED BREAST CANCER

15.30

Biomarker driven treatment sequencing for HR+ ABC: attempt to reconcile science and label indications

15.50

HER2+ disease: integrating the drug tsunami

16.10

TNBC: challenges and opportunities

16.30

Q&A

17.00

Adjourn

18.00

Ceremony for the presentation of the University of Padua Award for Advances in Breast Cancer 2020 and best poster award

18.15

Lecture of the Awardee

18.45

Cocktail

Saturday, October 10^th

9.00

Multidisciplinary Tumor Board 3 – Management of Advanced Breast Cancer

• Clinical case: molecular tumor board and liquid biopsy
• Clinical case: when to stop active therapy
• Clinical case: oligometastatic disease
• Clinical case: slowly progressive disease
• Clinical case: visceral crisis from luminal breast cancer

10.30

Coffee break

 

SESSION VII - AFFORDABILITY OF BREAST CANCER COSTS AND EQUITY IN ACCESS

11.00

Disparities in drug access across Europe

11.20

The US system: lights and shadows

11.40

Reimbursment process in Italy

12.00

Real World Evidence in Oncology: Opportunities and Pitfalls

12.20

The wave of biosimilars

12.40

The EBCC 2020 Manifesto: how to translate this to clinical reality

13.00

Q&A

13.15

Adjourn and final evaluation questionnaire

Participants can send one or more abstracts.

The form should be filled out by following specific guidelines:

• Use the capitol letter for the title
• Indicate each author's affiliation (that should include institution, department and town)
• Underline the designated presenting author’s name.
• Use font Times New Roman 10, single line spacing.

Abstracts will be selected by the Scientific Committee and will be shown during the poster session on October 9^th from 8 am. Poster size: 70 cm wide and 100 cm high (portrait).

People sending the selected abstracts will have free registration, dinners and accommodation as well as a reimbursement of travel expenses (max of travel reimbursement € 200,00 for Italian participants and € 300,00 for European participants).

Abstracts should be sent within July 21^st. A confirmation will be sent by email within September 10^th.

Download Form

Send abstract

Registration Fee

€ 250,00

€ 150,00 For graduate students and nurses

Tax free.

They includes the conference bag, the conference book and all coffee breaks and lunches. They do not include Hotel accomodation, dinners and travel expenses.